Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine

作者: Meng Xu-Welliver , José Leitão , Sreenivas Kanugula , William J Meehan , Anthony E Pegg

DOI: 10.1016/S0006-2952(99)00216-6

关键词: DNA repairBiologyComplementary DNAMolecular biologyDNAMutantPlasmidAlkyltransferaseO6-BenzylguanineGeneBiochemistry

摘要: O6-Alkylguanine-DNA alkyltransferase (AGT) is a DNA repair protein that provides protection from alkylating agents such as dacarbazine, temozolomide, and 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), which are used for cancer chemotherapy. O6-Benzylguanine (BG) an inhibitor of AGT sensitizes tumors to these agents. BG currently in clinical trials. It possible the presence resistant forms may limit effectiveness this strategy. Previous studies have shown mutant G160R, occur naturally result polymorphism gene, BG, whereas mutants G160W G160A actually more sensitive inhibitor. To examine other mutations at site, random sequence was placed codon 160 cDNA, plasmid library constructed express sequences Escherichia coli. After selection with N-methyl-N'-nitro-N-nitrosoguanidine, BG-resistant were obtained analyzed. Eleven different amino acid substitutions found impart resistance by assay. The most contained histidine or arginine, had EC50 values 12 4.7 microM, respectively, compared wild-type 0.08 but nine alterations led least 10-fold rise value. Three additional site-directed mutagenesis, 6- 11-fold increases BG. Comparisons properties G160R G160E showed enhanced reaction much strongly when acidic residue present position. This account lack mutation even though it did These results indicate many position can lead significant

参考文章(26)
Sreenivas Kanugula, Meng Xu-Welliver, Anthony E. Pegg, Isolation of Human O6-Alkylguanine-DNA Alkyltransferase Mutants Highly Resistant to Inactivation by O6-Benzylguanine Cancer Research. ,vol. 58, pp. 1936- 1945 ,(1998)
B A Stanley, A E Pegg, I Holm, Site of pyruvate formation and processing of mammalian S-adenosylmethionine decarboxylase proenzyme. Journal of Biological Chemistry. ,vol. 264, pp. 21073- 21079 ,(1989) , 10.1016/S0021-9258(19)30047-X
Karina Goodtzova, Anthony E. Pegg, Tina M. Crone, Suvarchala Edara, Mutations in Human O6-Alkylguanine-DNA Alkyltransferase Imparting Resistance to O6-Benzylguanine Cancer Research. ,vol. 54, pp. 6221- 6227 ,(1994)
Sreenivas Kanugula, Karina Goodtzova, Anthony E. Pegg, Suvarchala Edara, Resistance of the Human O6-Alkylguanine-DNA Alkyltransferase Containing Arginine at Codon 160 to Inactivation by O6-Benzylguanine Cancer Research. ,vol. 56, pp. 5571- 5575 ,(1996)
Lance P. Encell, Lawrence A. Loeb, Melissa M. Coates, Engineering human DNA alkyltransferases for gene therapy using random sequence mutagenesis Cancer Research. ,vol. 58, pp. 1013- 1020 ,(1998)
A E Pegg, M E Dolan, O6-benzylguanine and its role in chemotherapy. Clinical Cancer Research. ,vol. 3, pp. 837- 847 ,(1997)
M.H. Moore, J.M. Gulbis, E.J. Dodson, B. Demple, P.C. Moody, Crystal structure of a suicidal DNA repair protein: the Ada O6-methylguanine-DNA methyltransferase from E. coli. The EMBO Journal. ,vol. 13, pp. 1495- 1501 ,(1994) , 10.1002/J.1460-2075.1994.TB06410.X
H S Friedman, D M Kokkinakis, J Pluda, A H Friedman, I Cokgor, M M Haglund, D M Ashley, J Rich, M E Dolan, A E Pegg, R C Moschel, R E McLendon, T Kerby, J E Herndon, D D Bigner, S C Schold, Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma Journal of Clinical Oncology. ,vol. 16, pp. 3570- 3575 ,(1998) , 10.1200/JCO.1998.16.11.3570